Feature|Articles|September 18, 2026

Understanding the Latest with MFN Pricing and What It Means to Pharma

Author(s)Alan Crowther

EVERSANA's Alan Crowther on why MFN's three programs, compounding interactions with IRA and 340B, and leverage gaps make it pharma's most consequential pricing challenge.

On August 31, the Trump Administration expanded its Most-Favored-Nation (MFN) drug pricing initiative by securing agreements with nine additional pharmaceutical companies. Pharmaceutical Executive connected with Alan Crowther, who leads EVERSANA’s global pricing and access business and the company’s leading pricing platform, Navlin, to discuss what the updates to MFN could mean to the industry.

Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.